New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
06:10 EDTSGYPSynergy Pharmaceuticals' plecanatide shows positive results in Phase 2B study
Synergy Pharmaceuticals announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 patients with irritable bowel syndrome with constipation. The primary objective of this trial was to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients. Plecanatide demonstrated statistically significant improvement in complete spontaneous bowel movement frequency – the study’s primary endpoint – and was safe and well tolerated. The most common event was diarrhea, which occurred in 9.3% of the 3.0mg plecanatide-treated patients. The company intends to initiate pivotal phase 3 trials in IBS-C patients in 2H14.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTSGYPSynergy Pharm says analysis shows Phase 2 SP-333 trial met primary endpoint
Subscribe for More Information
November 10, 2014
16:30 EDTSGYPGreat Point Partners reports 6.35% passive stake in Synergy Pharmaceuticals
16:11 EDTSGYPSynergy Pharmaceuticals reports Q3 EPS (24c), consensus (28c)
Synergy's cash, cash equivalents and available-for-sale securities balance as of September 30 was $32.7M as compared to $68.1M on December 31, 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use